导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.38% | 1890/4773 |
| 近一周 | -2.18% | 1411/5462 |
| 近一月 | -4.38% | 2426/5421 |
| 近一季 | -6.22% | 2023/5209 |
| 近半年 | 1.27% | 1069/4920 |
| 近一年 | 3.85% | 1837/4366 |
| 近两年 | 52.77% | 1401/2954 |
| 近三年 | 36.77% | 813/2253 |
| 成立以来 | 75.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.38% 3613/4961 |
16.81% 1523/5312 |
- - |
- - |
| 2025 | 21.34% 2040/4813 |
0.37% 1884/3635 |
2.89% 1282/4076 |
17.56% 2476/4524 |
-0.06% 2334/4813 |
| 2024 | 19.17% 547/3463 |
3.05% 630/2808 |
-0.23% 714/3014 |
15.67% 1656/3129 |
0.20% 1251/3463 |
| 2023 | -8.55% 1028/2656 |
3.27% 1227/2280 |
-3.45% 797/2385 |
-2.19% 635/2515 |
-6.23% 1681/2655 |
| 2022 | -17.51% 601/2207 |
-11.88% 552/1919 |
5.48% 894/2016 |
-12.66% 753/2113 |
1.61% 1203/2208 |
| 2021 | 5.86% 532/1822 |
0.45% 295/1255 |
6.78% 720/1330 |
-4.09% 679/1466 |
2.90% 500/1822 |
| 2020 | 40.45% 310/1250 |
-8.85% 635/1028 |
13.75% 596/1067 |
18.76% 75/1164 |
14.06% 303/1184 |
| 2019 | - - |
- - |
- - |
- - |
8.71% 296/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 银河沪深300指数增强A VS. 长安沪深300非周期A(740101) |